15 Drugs Approved Globally in January 2026: Key Takeaways for Pharma Professionals

The first month of 2026 set a productive tone for the global pharmaceutical industry. Fifteen drugs received regulatory approval across five regions — China, the United States, South Korea, Canada, and the European Union — spanning a wide range of therapeutic areas from metabolic disease to rare genetic disorders.

This roundup, powered by data from Patsnap Synapse, breaks down every approval, highlights the most significant new treatments, and identifies the pipeline trends shaping the year ahead. All clinical trial references link to entries on ClinicalTrials.gov, the official registry maintained by the US National Library of Medicine.

Global Drug Approvals at a Glance: January 2026

Breakdown by Region

China led with 8 approvals, continuing its strong regulatory momentum and demonstrating the maturation of its domestic biopharma ecosystem. Chinese approvals spanned oncology, metabolic disease, infectious disease prevention, and aesthetics.

The United States contributed 2 approvals, both addressing conditions with significant unmet need: presbyopia (age-related near-vision loss affecting hundreds of millions globally) and Menkes disease, a life-threatening rare pediatric disorder.

South Korea added 3 approvals, primarily in common but high-volume therapeutic areas: cold and flu symptom management, gastric ulcers, and topical anti-inflammatory treatment.

Canada and the European Union each contributed one approval — Nitroxoline for amebiasis and a biosimilar of Teduglutide for Short Bowel Syndrome, respectively.

Most Significant Approvals of the Month

Copper Histidine (USA) — A Rare Disease Milestone

Approved on January 12, Copper Histidine marks the first approved therapy for Menkes Kinky Hair Syndrome in the United States, a rare X-linked copper metabolism disorder that affects approximately 1 in 100,000–250,000 live male births. According to the National Institute of Neurological Disorders and Stroke (NINDS), the condition is characterized by progressive neurodegeneration and connective tissue abnormalities stemming from impaired copper transport. Developed by Sentynl Therapeutics, the approval is based on pivotal trials NCT00811785 and NCT00001262. The drug targets ATP7A, the copper-transporting ATPase whose dysfunction underlies the disease. For rare disease researchers and investors, this is a landmark approval demonstrating that decades of mechanistic research can ultimately translate into approved treatments. [Read our full Copper Histidine deep dive →]

Ecnoglutide (China) — A New GLP-1 Contender

Ecnoglutide, a recombinant GLP-1 receptor agonist developed by Hangzhou Sciwind Biosciences, was approved in China for Type 2 Diabetes on January 27. As the GLP-1 space becomes one of the most competitive in biopharma — with Tirzepatide and Semaglutide dominating global markets — Ecnoglutide represents China’s ambition to develop homegrown alternatives. Analysts watching the metabolic disease space should track how this drug performs commercially and whether it enters global trials.

Retlirafusp alfa (China) — A Dual-Target Oncology Agent

Retlirafusp alfa is a novel antibody fusion protein targeting both TGFBR2 and PD-L1, approved in China for PD-L1-positive gastroesophageal junction adenocarcinoma and stomach cancer. This dual-targeting approach reflects the broader industry shift away from single-checkpoint inhibitors toward combination immunotherapy strategies. Developed by Suzhou Suncadia Biopharmaceuticals, it is an example of the sophisticated biologics now emerging from China’s oncology pipeline.

Teduglutide Biosimilar (EU) — Biosimilar Expansion Continues

The European approval of Viatris’s Teduglutide biosimilar for Short Bowel Syndrome signals continued growth of the biosimilar market in rare GI diseases. As reference products lose exclusivity, biosimilar entrants are expected to improve patient access and reduce healthcare costs across Europe.

Therapeutic Area Trends

Metabolic disease was the most active area by drug count, with two diabetes approvals (Ecnoglutide and Olorigliflozin) and ongoing pipeline activity in GLP-1 and SGLT2 pathways.

Oncology saw high-complexity approvals in January, with Retlirafusp alfa’s dual-checkpoint mechanism and Human Thyrotropin beta for thyroid carcinoma both reflecting targeted innovation.

Rare diseases punched above their weight in terms of significance, with Copper Histidine (Menkes disease) and the Teduglutide biosimilar (Short Bowel Syndrome) both addressing conditions where patients have historically had few or no options.

Infectious disease prevention was represented by two Chinese influenza vaccine approvals — a reminder that vaccine development remains a priority in the post-pandemic landscape.

What This Means for R&D and Business Development Teams

For drug developers and BD professionals, January’s approval landscape offers several signals:

💡 Want to benchmark your pipeline against January’s approvals? Search the full drug database on Patsnap Synapse →

• GLP-1 competition is intensifying globally. Multiple GLP-1 agents are now approaching approval or expedited review status in multiple regions simultaneously.
• Chinese biopharma is maturing. Eight approvals in a single month, including sophisticated biologics and novel mechanisms, underscore China’s growing role as an originator, not just a manufacturer.
• Rare disease investment is paying off. Copper Histidine’s approval, built on decades of mechanistic research into ATP7A biology, validates the long-term patient and scientific case for rare disease R&D.
• Biosimilar market expansion continues. With Teduglutide now joined by a biosimilar in Europe, BD teams should model biosimilar entry timelines for other late-stage reference products.

Track the Full Drug Pipeline with Patsnap Synapse

The approvals in this roundup represent only a fraction of the global drug development activity underway. Patsnap Synapse connects patent data, clinical trial records, regulatory filings, and competitive landscape intelligence across 130,000+ new drugs and 48,000+ targets — updated in real time.

Whether you’re conducting target validation, freedom-to-operate analysis, or competitive benchmarking, Synapse gives life sciences teams the intelligence to move faster and decide smarter.

Explore Patsnap Synapse →

Data sourced from Patsnap Synapse. All approval information is current as of January 2026. This report is for informational purposes only.